Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. The company operates within the biopharmaceutical and infectious disease sectors, with a strategic emphasis on structure-based drug design to target viral replication mechanisms. Its core research programs address significant unmet medical needs in viral diseases, including influenza, coronavirus, and norovirus infections.
The company does not currently have any FDA-approved products and does not generate material commercial revenue. Instead, its primary value proposition lies in its proprietary drug discovery platform and preclinical and clinical development pipeline. Cocrystal Pharma, Inc. was originally incorporated in 1986 under a different name and business model and later transitioned into an antiviral-focused biotechnology company through restructuring and acquisitions in the mid-2010s, including the formation of its drug discovery subsidiary to support its current scientific strategy.
Business Operations
Cocrystal Pharma, Inc. conducts operations primarily through its wholly owned subsidiary, Cocrystal Discovery, Inc., which houses its core research and development activities. The company’s operations are centered on identifying and optimizing small-molecule antiviral candidates using advanced structural biology, including crystallography and computational chemistry, to inhibit viral enzymes essential for replication.
The company’s business model is R&D-driven, with expenditures focused on laboratory research, preclinical studies, and early-stage clinical trials. Operations are predominantly domestic, with research activities conducted in the United States. As of publicly available disclosures, the company has not reported material revenue from product sales, and funding has historically been derived from equity offerings and other financing activities. Data on significant commercial partnerships, licensing agreements, or joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Cocrystal Pharma, Inc. positions itself as a specialized antiviral innovator leveraging structure-based drug design to improve efficacy and resistance profiles of antiviral agents. Its growth initiatives are centered on advancing its pipeline candidates through clinical development and seeking potential strategic collaborations or licensing opportunities once clinical proof-of-concept is achieved.
The company’s investment focus is internal, prioritizing continued funding of its antiviral programs rather than broad diversification or large-scale acquisitions. Cocrystal Discovery, Inc. represents its most significant subsidiary investment and serves as the foundation for its intellectual property portfolio. The company is engaged in emerging antiviral research areas, particularly next-generation inhibitors targeting conserved viral proteins, though timelines and commercial outcomes remain uncertain based on publicly available information.
Geographic Footprint
Cocrystal Pharma, Inc. is headquartered in the United States, with its principal executive offices and research operations located in California. The company’s operational footprint is largely domestic, reflecting its status as a development-stage biotechnology firm without commercial manufacturing or distribution activities.
International presence is limited and primarily indirect, consisting of intellectual property filings and scientific engagement rather than physical operations or foreign subsidiaries. The company does not currently report significant international revenue, manufacturing facilities, or large-scale overseas investments based on public disclosures.
Leadership & Governance
Cocrystal Pharma, Inc. is led by an executive team with backgrounds in biotechnology, drug development, and corporate finance. The leadership’s stated strategic vision emphasizes disciplined capital allocation, scientific rigor, and advancing antiviral candidates toward clinical and commercial viability.
Key executives include:
- Sam Lee, Ph.D. – President and Chief Executive Officer
- James Martin – Chief Financial Officer
- Geoffrey Hall – Chief Scientific Officer
Information regarding founders and historical leadership roles varies across public disclosures; therefore, founder attribution and earlier governance details are inconclusive based on available public sources. The company operates under a standard U.S. public company governance framework, overseen by a board of directors with experience in life sciences and corporate management.